Analysis of serum microRNA-122 in a randomised controlled trial of N-acetylcysteine for treatment of anti-tuberculosis drug-induced liver injury.
Muhammed Shiraz MoosaGiusy RussomannoJeffrey R DorfmanHannah GunterChandni PatelEithne CostelloDan CarrGary MaartensDaniel F CarrChristopher GoldringKaren CohenPublished in: British journal of clinical pharmacology (2023)
MiR-122 concentrations in our participants with AT-DILI were considerably higher than previously reported in healthy volunteers and in patients on anti-tuberculosis therapy without liver injury. We did not detect an effect of NAC on miR-122 concentrations. Further research is needed to determine the utility of miR-122 in the diagnosis and management of AT-DILI.
Keyphrases
- drug induced
- liver injury
- cell proliferation
- long non coding rna
- long noncoding rna
- adverse drug
- end stage renal disease
- mycobacterium tuberculosis
- chronic kidney disease
- ejection fraction
- newly diagnosed
- prognostic factors
- transcription factor
- hiv aids
- emergency department
- stem cells
- mesenchymal stem cells
- patient reported outcomes
- hiv infected
- cell therapy
- antiretroviral therapy